Hafiz Mahboob, MD
Pulmonary Disease · Reno, NVNPI 1477947612
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,065 of the $2,346 with a category attached, or 88.0%. 19 manufacturers reported payments, led by GSK at 25.9% of the total. 2025 is the largest year on record at $760, more than ten times the $16 reported in 2021.
Across 111 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$607
- Johnson & Johnson$333
- Boehringer Ingelheim$282
- AstraZeneca$256
- Mylan Specialty L.p.$146
- Grifols USA, LLC$128
- plus $594 from 13 others
What the payments were for
- Travel & lodging$26011%
- Food & beverage$2,06588%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $607 |
| Johnson & Johnson | 4 | $333 |
| Boehringer Ingelheim | 15 | $282 |
| AstraZeneca | 12 | $256 |
| Mylan Specialty L.p. | 6 | $146 |
| Grifols USA, LLC | 7 | $128 |
| Insmed, Inc. | 5 | $79 |
| Viatris Specialty LLC | 3 | $77 |
| CSL Behring | 3 | $69 |
| Sanofi | 3 | $64 |
| Amgen | 3 | $50 |
| Merck | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 1 | $39 |
| Pulmonx Corporation | 2 | $37 |
| Shionogi Inc | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Chiesi USA, Inc. | 2 | $29 |
| United Therapeutics Corporation | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$260
How this compares
$2,346 in reported general payments places this provider in the 55th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 172 | $131,819 |
| Spiriva RespimatTiotropium Bromide | 94 | $62,889 |
| Breo ElliptaFluticasone/Vilanterol | 95 | $42,574 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 52 | $34,171 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $32,115 |
| DuleraMometasone/Formoterol | 18 | $9,341 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $9,273 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $8,270 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 57 | $7,287 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $5,033 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $4,092 |
| Arnuity ElliptaFluticasone Furoate | 15 | $3,711 |
| AlvescoCiclesonide | 12 | $3,234 |
| Ventolin HfaAlbuterol Sulfate | 39 | $2,508 |
| Fluticasone Propionate | 120 | $1,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $607 | $187,376310 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $282 | $97,060146 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $256 | $40,38665 claims |
| MerckDulera | $45 | $9,34118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Reno
- Charles StahlmannReno$263K
- William GrahamReno$21K
- Amanda MorganReno$20K
- Steve MashourReno$12K
- Julia ChristopherReno$8K
- Christina SzotReno$7K
- Aleem SuraniReno$2K
- Kunwardeep DhillonReno$2K
- Aaron VirayReno$2K
- Shibu SkariaReno$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.